organization · Reporting owner
Lux Venture Partners IV, LLC
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Science 37 Holdings, Inc.SNCE · Entity 15235 | 10% owner | April 04, 2022 | April 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Science 37 Holdings, Inc.
Report date April 04, 2022 · Filed April 06, 2022
Jointly reported with Lux Capital Management, LLC, Lux Ventures IV, L.P., Lux Co-Invest Opportunities, L.P., Lux Co-Invest Partners, LLC, Hebert Peter, Wolfe Josh
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Lux Ventures IV, L.P. | 8,743,999 |
Reported balance
After 2022-04-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-04-04 · Other · Disposed 2,914,667 · Balance 8,743,999 F1: Pro rata distribution of 2,914,667 shares from Lux Ventures IV, L.P. to its partners. F2: Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares held by Lux Ventures IV, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares held by Lux Co-Invest Opportunities, L.P. Peter Hebert and Joshua Wolfe are the individual managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC and may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P., Lux Capital Management, LLC, as the investment manager for each of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3: Each of Lux Capital Management, LLC, Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Peter Hebert and Joshua Wolfe disclaim beneficial ownership over the shares reported herein except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Lux Co-Invest Opportunities, L.P. | 3,505,890 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,505,890 F2: Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares held by Lux Ventures IV, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares held by Lux Co-Invest Opportunities, L.P. Peter Hebert and Joshua Wolfe are the individual managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC and may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P., Lux Capital Management, LLC, as the investment manager for each of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3: Each of Lux Capital Management, LLC, Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Peter Hebert and Joshua Wolfe disclaim beneficial ownership over the shares reported herein except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Pro rata distribution of 2,914,667 shares from Lux Ventures IV, L.P. to its partners.
F2: Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares held by Lux Ventures IV, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares held by Lux Co-Invest Opportunities, L.P. Peter Hebert and Joshua Wolfe are the individual managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC and may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P., Lux Capital Management, LLC, as the investment manager for each of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P.
F3: Each of Lux Capital Management, LLC, Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Peter Hebert and Joshua Wolfe disclaim beneficial ownership over the shares reported herein except to the extent of their pecuniary interest therein, if any.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aeva Technologies, Inc.
Report date August 05, 2022 · Filed August 09, 2022
Jointly reported with Hebert Peter, Wolfe Josh, Lux Ventures IV, L.P., Lux Co-Invest Opportunities, L.P., Lux Co-Invest Partners, LLC
Section 16 reporting ended · disclosed 2022-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 14,692,316 |
Reported balance
After 2022-08-05 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2022-08-05 · Other · Disposed 7,346,159 · Balance 14,692,316 F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,959,371 |
Reported balance
Holding disclosure · report date 2022-08-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,959,371 F2: These shares are owned directly by Lux Co-Invest Opportunities, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.
F2: These shares are owned directly by Lux Co-Invest Opportunities, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest.
Latch, Inc.
Report date September 28, 2021 · Filed October 05, 2021
Jointly reported with Lux Ventures IV, L.P., Lux Co-Invest Opportunities, L.P., Lux Co-Invest Partners, LLC, Hebert Peter, Wolfe Josh
Section 16 reporting ended · disclosed 2021-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,228,469 |
Reported balance
After 2021-09-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-09-28 · Other · Disposed 2,409,489 · Balance 7,228,469 F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,084,493 |
Reported balance
After 2021-09-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-09-28 · Other · Disposed 1,358,164 · Balance 4,084,493 F2: Pro rata distribution from Lux Co-Invest Opportunities, L.P. to its partners. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.
F2: Pro rata distribution from Lux Co-Invest Opportunities, L.P. to its partners. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest.
RECURSION PHARMACEUTICALS, INC.
Report date December 07, 2021 · Filed December 09, 2021
Jointly reported with Lux Ventures IV, L.P., Lux Co-Invest Opportunities, L.P., Lux Co-Invest Partners, LLC, Hebert Peter, Wolfe Josh
Section 16 reporting ended · disclosed 2021-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 13,021,519 |
Reported balance
After 2021-12-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-12-07 · Other · Disposed 4,265,576 · Balance 13,021,519 F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2022 Filed Aug 9, 2022 17:01 UTC | Aeva Technologies, Inc. AEVA · Entity 4949 | OtherCommon Stock | 7,346,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-021786 · ownership.xml · nonDerivative · entry 1 Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,692,316 F1 · kind: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. F1 · ownership.nature: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 20:43 UTC | Science 37 Holdings, Inc. SNCE · Entity 15235 | OtherCommon Stock | 2,914,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-22-000545 · science_fm4apr42022.xml · nonDerivative · entry 1 Lux Capital Management, LLC · CIK 0001592843 · 10% owner Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Lux Ventures IV, L.P. Disclosed balance after: 8,743,999 F1 · kind: Pro rata distribution of 2,914,667 shares from Lux Ventures IV, L.P. to its partners. F2 · ownership.nature: Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares held by Lux Ventures IV, L.P. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares held by Lux Co-Invest Opportunities, L.P. Peter Hebert and Joshua Wolfe are the individual managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC and may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P., Lux Capital Management, LLC, as the investment manager for each of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power over the shares held by each of Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Capital Management, LLC, Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, Peter Hebert and Joshua Wolfe disclaim beneficial ownership over the shares reported herein except to the extent of their pecuniary interest therein, if any. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 20:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A common stock | 4,265,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001582 · recursion_fm4dec72021.xml · nonDerivative · entry 1 Lux Ventures IV, L.P. · CIK 0001633331 · Former 10% Owner Lux Venture Partners IV, LLC · CIK 0001633332 · Former 10% Owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · Former 10% Owner Lux Co-Invest Partners, LLC · CIK 0001722021 · Former 10% Owner Hebert Peter · CIK 0001683771 · Former 10% Owner Wolfe Josh · CIK 0001830001 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,021,519 F1 · kind: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. F1 · ownership.direct: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 28, 2021 Filed Oct 5, 2021 16:31 UTC | Latch, Inc. LTCH · Entity 9606 | OtherCommon Stock | 1,358,164 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001276 · latch_fm4sep282021.xml · nonDerivative · entry 2 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,084,493 F2 · kind: Pro rata distribution from Lux Co-Invest Opportunities, L.P. to its partners. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest. F2 · ownership.nature: Pro rata distribution from Lux Co-Invest Opportunities, L.P. to its partners. Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. The Individual Lux Managers are the individual managing members of Lux Co-Invest Partners, LLC. The Individual Lux Managers, as the sole managers of Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Co-Invest Opportunities, L.P. Each of Lux Co-Invest Partners, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest. Read SEC document |
| September 28, 2021 Filed Oct 5, 2021 16:31 UTC | Latch, Inc. LTCH · Entity 9606 | OtherCommon Stock | 2,409,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001276 · latch_fm4sep282021.xml · nonDerivative · entry 1 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,228,469 F1 · kind: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. F1 · ownership.nature: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 16:56 UTC | Aeva Technologies, Inc. AEVA · Entity 4949 | OtherCommon Stock | 7,346,159 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001184 · aevatech_fm4sep82021.xml · nonDerivative · entry 1 Hebert Peter · CIK 0001683771 · 10% owner Wolfe Josh · CIK 0001830001 · 10% owner Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,038,475 F1 · kind: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. F1 · ownership.nature: Pro rata distribution from Lux Ventures IV, L.P. to its partners. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC (the "Individual Lux Managers"). The Individual Lux Managers, as the sole managers of Lux Venture Partners IV, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. Each of Lux Venture Partners IV, LLC and the Individual Lux Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 21:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries D Preferred Stock · Derivative | 1,490,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 8 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,490,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F10 · shares: Represents 298,156 shares held of record by Lux Ventures IV, L.P. and 1,192,627 shares held of record by Lux Co-Invest Opportunities, L.P. F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F10 · derivative.underlying_shares: Represents 298,156 shares held of record by Lux Ventures IV, L.P. and 1,192,627 shares held of record by Lux Co-Invest Opportunities, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 21:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries C Preferred Stock · Derivative | 1,825,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 7 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,825,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F9 · shares: Represents shares held of record by Lux Co-Invest Opportunities, L.P. F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F9 · derivative.underlying_shares: Represents shares held of record by Lux Co-Invest Opportunities, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 21:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries B Preferred Stock · Derivative | 3,578,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 6 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,578,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F8 · shares: Represents shares held of record by Lux Ventures IV, L.P. F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F8 · derivative.underlying_shares: Represents shares held of record by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 21:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries A Preferred Stock · Derivative | 10,279,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027701 · doc4.xml · derivative · entry 5 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 10,279,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F8 · shares: Represents shares held of record by Lux Ventures IV, L.P. F5 · derivative.exercise_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.expiration_date: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F5 · derivative.underlying: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F8 · derivative.underlying_shares: Represents shares held of record by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 21:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 17,187,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 4 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,287,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P. F7 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. F6 · balance_after: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 21:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionCommon Stock | 17,187,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 3 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P. F7 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 21:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionCommon Stock | 17,174,594 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 2 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 17,187,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: 3,018,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,156,084 of these shares are held by Lux Ventures IV, L.P. F5 · price: Each share of Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Class A Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Class A Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Class A Common Stock had no expiration date. F6 · balance_after: 3,068,510 of these shares are held by Lux Co-Invest Opportunities, L.P. and 14,206,084 of these shares are held by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 21:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 100,000 | $18.00 | $1,800,000.00 |
DisclosureSEC source: 0001209191-21-027701 · doc4.xml · nonDerivative · entry 1 Lux Ventures IV, L.P. · CIK 0001633331 · 10% owner Lux Co-Invest Opportunities, L.P. · CIK 0001722022 · 10% owner Lux Co-Invest Partners, LLC · CIK 0001722021 · 10% owner Lux Venture Partners IV, LLC · CIK 0001633332 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 100,000 F1 · balance_after: 50,000 of these shares are held by Lux Co-Invest Opportunities, L.P. and 50,000 of these shares are held by Lux Ventures IV, L.P. F2 · ownership.nature: Lux Co-Invest Partners, LLC is the general partner of Lux Co-Invest Opportunities, L.P. and exercises voting and dispositive power over the shares noted herein held by Lux Co-Invest Opportunities, L.P. Lux Venture Partners IV, LLC is the general partner of Lux Ventures IV, LP and exercises voting and dispositive power over the shares noted herein held by Lux Ventures IV, L.P. Peter Hebert and Josh Wolfe are the individual managing members of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, or the Individual Managers. The Individual Managers, as the sole managers of Lux Venture Partners IV, LLC and Lux Co-Invest Partners, LLC, may be deemed to share voting and dispositive power for the shares noted herein held by Lux Ventures IV, L.P. and Lux Co-Invest Opportunities, L.P. F3 · ownership.nature: Each of Lux Venture Partners IV, LLC, Lux Co-Invest Partners, LLC, and the Individual Managers separately disclaim beneficial ownership over the shares noted herein except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.